|Bid||162.90 x 6700|
|Ask||162.95 x 11200|
|Day's Range||160.80 - 164.00|
|52 Week Range||135.00 - 202.80|
|Beta (5Y Monthly)||0.70|
|PE Ratio (TTM)||24.32|
|Earnings Date||Nov 09, 2023|
|Forward Dividend & Yield||2.20 (1.36%)|
|Ex-Dividend Date||May 02, 2023|
|1y Target Est||187.20|
Subscribe to Yahoo Finance Plus to view Fair Value for MRK.DE
Germany's Merck KGaA said its experimental multiple sclerosis drug evobrutinib did not meet the primary goal in highly anticipated late-stage trials, dealing a major blow to the company's growth ambitions. In the Phase III trials, evobrutinib failed to reduce the annualized relapse rate compared to Sanofi's Aubagio in patients with relapsing multiple sclerosis, Merck said in a statement on Tuesday. Merck was seen as ahead of Sanofi, Novartis and Roche in a four-way race to develop more targeted MS drugs in a class known as Bruton’s tyrosine kinase (BTK) inhibitors.
Key Insights The projected fair value for Merck KGaA is €297 based on 2 Stage Free Cash Flow to Equity Current share...
Q3 2023 Exscientia PLC Earnings Call